Literature DB >> 3159531

Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure.

W B White, V E Smith, E J McCabe, M K Meeran.   

Abstract

To assess the clinical efficacy of chronic nitrendipine therapy in mild to moderate essential hypertension, we studied blood pressure (BP) and heart rate responses in 22 subjects receiving maintenance nitrendipine therapy. Ten subjects (45%) whose hypertension was controlled with chronic monotherapy had an 11/12 mm Hg decrease in supine BP (P less than 0.05) with a mean (+/- SD) dose of 71 +/- 15 mg/day. The 12 (55%) subjects whose hypertension was not controlled with monotherapy had a comparatively higher baseline BP than the other 10 (156/105 +/- 10/6 compared with 150/98 +/- 15/4 mm Hg; P less than 0.05). Eight of the 10 subjects demonstrating office BP control with chronic nitrendipine monotherapy who also had full-time employment underwent continuous ambulatory BP monitoring before and after maintenance monotherapy. Nitrendipine induced a reduction in the mean 24-hour BP and mean BP at home, but did not reduce the BP during work or while asleep. These data suggest that nitrendipine lowers BP when assessed by casual office methods. The ambulatory BP monitor data demonstrate that the hypotensive response to chronic nitrendipine is modified during work periods, which are generally associated with increased adrenergic activity. Ambulatory BP monitoring may be superior to office (casual) monitoring in the assessment of the overall efficacy of antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159531     DOI: 10.1038/clpt.1985.135

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

2.  Ambulatory blood pressure monitoring for the assessment of nicardipine as a third drug in severe essential hypertension.

Authors:  Y Lacourcière; L Poirier; C Lévesque; P Provencher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension.

Authors:  D Maclean; E T Mitchell; R Lewis; N Irvine; J S McLay; J McEwen; R R Coulson; N D Slater; T J Fitzsimons; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

Review 4.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

5.  Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension.

Authors:  A G Dupont; J M Coupez; P Jensen; R Coupez-Lopinot; D F Schoors; P Hermanns; M Nicolas
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

6.  Nitrendipine in human plasma and breast milk.

Authors:  W B White; S C Yeh; G J Krol
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.